Skip to content

Inspection Record

Medlmmune UK Limited (AstraZeneca/Supply Biologics) — FDA 483 Findings

US FDAInspected 2022-06-14Published 2026-10-30 4 findingsDeviation, CAPA, and investigationOther quality systemValidation and qualification

View the regulator's official source The source document is always the basis for judgement.

Findings

1Deviation, CAPA, and investigation

Your firm did not notify the license holder ofa deviation that may potentially affect the quality of a distributed drug product.

2Other quality system

The bacterial endotoxin procedure is deficient to ensure adequate detection of endotoxin in the samples.

3Validation and qualification

Critical reagents are not always qualified prior to release for use in the manufacturing ofU.S.

4Validation and qualification

There is a lack ofvalidation to support on assigned expiry.

A record as of the US FDA document published on 2026-10-30. Check the agency's announcements for any later corrective action, and rely on the original text. Translation and classification are machine-made.

Medlmmune UK Limited (AstraZeneca/Supply Biologics) company profile — full historyAll US FDA findings US FDA documents, 2026 Go to Findings search
Linked from (backlinks)
Briefs that featured this document
Weekly Newsletter

Get new findings like these every Monday

Every Monday we email the week's new findings and actions from the FDA, EMA, Health Canada and MFDS. Each one links to its record on our site, where you'll find the regulator's original document. We'll also let you know when the site gains new features. Unsubscribe any time with one click.

See recent findings first

Sent every Monday · a confirmation email follows when you subscribe · unsubscribe from the footer of any email.